Professor Sanjay Popat

Consultant Medical Oncologist BSc MBBS FRCP PhD

Specialism: Lung

Available at: Cavendish Square, Chelsea

Sanjay Popat, Consultant Medical Oncologist in the Lung Unit

Special interests:

  • Lung cancer
  • Mesothelioma
  • Thymoma

Biography

Professor Popat has both a private and an NHS practice at The Royal Marsden. He is a Consultant Medical Oncologist at The Royal Marsden, Professor of Thoracic Oncology at the Institute of Cancer Research, and is an internationally recognized expert in the treatment of lung cancer, mesothelioma and cancers of the thymus (thymoma and thymic carcinoma).

Professor Popat qualified in 1994 from Guy’s and St Thomas’ Hospitals with triple distinction and was awarded a PhD in Molecular Genetics in 2002, undertaking a postdoctoral Clinician Scientist Fellowship and a HEFCE Clinical Senior Lectureship thereafter. He has been awarded nationally and internationally competitive prizes for his research, in addition to four research fellowships. His research interests include the complexities of genetic profiling in cancer, as well as developing novel drug treatments through clinical trials.

He also holds several national and international roles. Nationally, Professor Popat Chairs the British Thoracic Oncology Group (BTOG) Steering Committee, is Co-Director for the NIHR London South Clinical Research Network Cancer Division, the NIHR Lung Cancer National Specialty Lead and is past Sub-group Chair of the NCRI Lung Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform (ETOP) and is active in the European Society of Medical Oncology (ESMO) where he has co-authored European Clinical Practice Guidelines for Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Mesothelioma. His research collaborations with industry have led to licensing of several drugs globally, leading to implementation in International treatment guidelines and NHS funding approvals.

Professor Popat is often an invited Clinical Expert to the National Institute for Health and Care Excellence (NICE) and sits on several committees overseeing the safety and governance for ongoing UK and international clinical trials. Sanjay is a strong advocate for patient education and support and is clinical advisor to several patient-facing cancer charities.

Clinical units